ATE308554T1 - Säugetier-telomerase - Google Patents

Säugetier-telomerase

Info

Publication number
ATE308554T1
ATE308554T1 AT95925552T AT95925552T ATE308554T1 AT E308554 T1 ATE308554 T1 AT E308554T1 AT 95925552 T AT95925552 T AT 95925552T AT 95925552 T AT95925552 T AT 95925552T AT E308554 T1 ATE308554 T1 AT E308554T1
Authority
AT
Austria
Prior art keywords
telomerase
mammal
therapeutic
pharmaceutical
useful
Prior art date
Application number
AT95925552T
Other languages
English (en)
Inventor
Bryant Villeponteau
Junli Feng
Walter Funk
William H Andrews
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/330,123 external-priority patent/US5583016A/en
Priority claimed from US08/472,802 external-priority patent/US5958680A/en
Priority claimed from US08/482,115 external-priority patent/US5776679A/en
Application filed by Geron Corp filed Critical Geron Corp
Application granted granted Critical
Publication of ATE308554T1 publication Critical patent/ATE308554T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C59/00Surface shaping of articles, e.g. embossing; Apparatus therefor
    • B29C59/02Surface shaping of articles, e.g. embossing; Apparatus therefor by mechanical means, e.g. pressing
    • B29C59/04Surface shaping of articles, e.g. embossing; Apparatus therefor by mechanical means, e.g. pressing using rollers or endless belts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121Hammerhead
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/13Decoys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT95925552T 1994-07-07 1995-07-06 Säugetier-telomerase ATE308554T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27210294A 1994-07-07 1994-07-07
US08/330,123 US5583016A (en) 1994-07-07 1994-10-27 Mammalian telomerase
US08/472,802 US5958680A (en) 1994-07-07 1995-06-07 Mammalian telomerase
US08/482,115 US5776679A (en) 1994-07-07 1995-06-07 Assays for the DNA component of human telomerase
PCT/US1995/008530 WO1996001835A1 (en) 1994-07-07 1995-07-06 Mammalian telomerase

Publications (1)

Publication Number Publication Date
ATE308554T1 true ATE308554T1 (de) 2005-11-15

Family

ID=27501040

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95925552T ATE308554T1 (de) 1994-07-07 1995-07-06 Säugetier-telomerase

Country Status (22)

Country Link
EP (2) EP1293565A3 (de)
JP (2) JPH10505488A (de)
KR (1) KR100789741B1 (de)
CN (1) CN1231491C (de)
AT (1) ATE308554T1 (de)
AU (1) AU696702B2 (de)
BG (1) BG63573B1 (de)
BR (1) BR9508254A (de)
CA (1) CA2194393C (de)
CZ (1) CZ3497A3 (de)
DE (1) DE69534568T2 (de)
DK (1) DK0778842T3 (de)
ES (1) ES2251720T3 (de)
FI (1) FI970026A7 (de)
HU (1) HUT78054A (de)
IS (1) IS4408A (de)
NO (1) NO970041L (de)
NZ (1) NZ289720A (de)
PL (1) PL181019B1 (de)
RO (1) RO117328B1 (de)
UA (1) UA47407C2 (de)
WO (1) WO1996001835A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5972605A (en) * 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
US5858777A (en) 1995-09-08 1999-01-12 Geron Corporation Methods and reagents for regulating telomere length and telomerase activity
US6582904B2 (en) 1995-11-16 2003-06-24 Michael W. Dahm Method of quantifying tumour cells in a body fluid and a suitable test kit
AU2593697A (en) * 1996-03-28 1997-10-17 Albert Einstein College Of Medicine Of Yeshiva University Transgenic organisms with altered telomerase activity
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
JPH1052300A (ja) * 1996-06-03 1998-02-24 Kyowa Hakko Kogyo Co Ltd 細胞内テロメラーゼ活性の測定法
JPH1028600A (ja) * 1996-07-17 1998-02-03 Kyowa Hakko Kogyo Co Ltd テロメラーゼ活性の測定法
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
IL129222A0 (en) * 1996-10-01 2000-02-17 Geron Corp Telomerase reverse transcriptase
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US5919656A (en) * 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
AU733610B2 (en) * 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
EP0981627B1 (de) * 1997-04-04 2003-09-17 Geron Corporation Gereinigte telomerase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
EP0990037A2 (de) * 1997-06-20 2000-04-05 Bayer Ag Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
EP1571215A3 (de) * 1997-07-01 2007-10-31 Cambia Biosystems LLC Gene und Proteine von vertebraten Telomerasen, und deren Verwendungen
JP2002514928A (ja) 1997-07-01 2002-05-21 キャンビア バイオシステムス リミティド ライアビリティー カンパニー 脊椎動物テロメラーゼ遺伝子およびタンパク質ならびにその使用
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
DE19757300A1 (de) * 1997-12-22 1999-06-24 Roche Diagnostics Gmbh Nachweis von Harnblasenkarzinom in einer Urinprobe
GB9801902D0 (en) 1998-01-29 1998-03-25 Cancer Res Campaign Tech A gene promoter
DE19804372A1 (de) 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
WO2000074667A2 (en) * 1999-06-04 2000-12-14 Au Jessie L S Compositions active in telomere damage comprising a taxane and telomerase inhibitor
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
ES2302701T3 (es) 1999-09-10 2008-08-01 Geron Corporation N3'-p5' tiofosforamidatos oligonucleotidicos: su sintesis y uso.
WO2001036971A1 (en) * 1999-11-16 2001-05-25 Kyowa Hakko Kogyo Co., Ltd. Method of searching for substance inhibiting binding between telomerase subunits
EA009442B1 (ru) * 2003-06-23 2007-12-28 Герон Корпорейшн Композиции и способы увеличения активности теломеразы
NZ545516A (en) 2003-09-09 2009-06-26 Geron Corp Modified oligonucleotides for telomerase inhibition
JP4635196B2 (ja) * 2005-03-04 2011-02-16 国立大学法人広島大学 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
SG175282A1 (en) 2009-04-21 2011-11-28 Genetic Technologies Ltd Methods for obtaining fetal genetic material
JP6021018B2 (ja) * 2011-05-30 2016-11-02 国立大学法人豊橋技術科学大学 改良されたオリゴヌクレオチドおよびそのオリゴヌクレオチドを含む医薬組成物
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
JP6556728B2 (ja) * 2013-09-13 2019-08-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ポリA−キャリヤーにより誘導される高分子量PCR生成物の生成を避けるためのオリゴ−dT分子の適用
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
KR101628890B1 (ko) * 2015-09-03 2016-06-09 주식회사 학표벽지 엠보싱 벽지 제조 장치
CN115678904B (zh) * 2021-07-22 2025-12-09 刘小川 一种突变的人端粒酶rna基因及其在预防和治疗泛癌种中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312686A (en) * 1980-02-11 1982-01-26 American Biltrite Inc. Printed and embossed floor covering and method and apparatus for its manufacture
JPH02179729A (ja) * 1988-12-30 1990-07-12 Shinetsu Kogyo Kk ゲートル巻きするラッピングフィルムの製造法
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
EP0666313A3 (de) * 1994-01-27 1996-03-06 Univ Iowa State Res Found Inc Telomerase als Ziel in der Gentherapie des Krebs.
US5876979A (en) * 1994-07-07 1999-03-02 Cold Spring Harbor Laboratory RNA component of mouse, rat, Chinese hamster and bovine telomerase
JPH08294966A (ja) * 1995-04-26 1996-11-12 Nippon Shokubai Co Ltd 樹脂成形品の連続成形方法
JPH10119130A (ja) 1996-10-22 1998-05-12 Japan Steel Works Ltd:The 連続発泡体の製造方法及び装置
KR100815605B1 (ko) * 2002-02-18 2008-03-20 바프렉스 주식회사 공압출 다층필름의 제조방법 및 장치

Also Published As

Publication number Publication date
BG63573B1 (bg) 2002-05-31
KR20050058527A (ko) 2005-06-17
DE69534568T2 (de) 2006-07-27
EP1293565A2 (de) 2003-03-19
NO970041D0 (no) 1997-01-06
NZ289720A (en) 1999-03-29
FI970026A0 (fi) 1997-01-03
HUT78054A (hu) 1999-07-28
CZ3497A3 (en) 1997-10-15
AU2964795A (en) 1996-02-09
CN1231491C (zh) 2005-12-14
EP0778842A4 (de) 1999-08-11
DK0778842T3 (da) 2006-03-20
DE69534568D1 (de) 2005-12-08
FI970026L (fi) 1997-03-03
EP1293565A3 (de) 2004-05-12
RO117328B1 (ro) 2002-01-30
CA2194393C (en) 2002-06-25
HK1011691A1 (en) 1999-07-16
JP4068861B2 (ja) 2008-03-26
CN1158617A (zh) 1997-09-03
CA2194393A1 (en) 1996-01-25
BR9508254A (pt) 1997-12-23
EP0778842A1 (de) 1997-06-18
EP0778842B1 (de) 2005-11-02
KR100789741B1 (ko) 2008-01-02
WO1996001835A1 (en) 1996-01-25
NO970041L (no) 1997-03-06
PL181019B1 (pl) 2001-05-31
JPH10505488A (ja) 1998-06-02
BG101103A (bg) 1997-10-31
UA47407C2 (uk) 2002-07-15
ES2251720T3 (es) 2006-05-01
IS4408A (is) 1997-01-03
AU696702B2 (en) 1998-09-17
JP2002272489A (ja) 2002-09-24
FI970026A7 (fi) 1997-03-03
PL318169A1 (en) 1997-05-26

Similar Documents

Publication Publication Date Title
ATE308554T1 (de) Säugetier-telomerase
WO1996001614A3 (en) Rna component of telomerase
TR199501021A2 (tr) Vücut agirligi modülatörüne tekabül eden nükleik asitler ve proteinler ve bunlarin diagnostik ve terapötik kullanimlari.
FI911152A7 (fi) Nukleiinihapposekvenssin amplifikaatiomenetelmät
FI922609L (fi) Proteiner och nukleinsyror.
DK0733069T3 (da) Oprensede Primat CTLA-8-antigener og beslægtede reagenser
FI924197A7 (fi) Reagensseja ja menetelmiä geeniekspression muuntamiseksi RNA:n jäljitt elyn avulla
ITTO950367A0 (it) Proteine di prrsv ricombinanti, corredi diagnostici e vaccini contenenti tali proteine di prrsv ricombinanti.
NO904633L (no) Amplifikasjon av nukleinsyrer ved transkriberbar haarnaalsprobe.
DE69635744D1 (de) Modifizierte Nukleinsäuresonden
ITRM930301A0 (it) Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
DK0991416T4 (da) Universelt anvendeligt blodplasma
DE3686527D1 (de) Mikro-rohrleitung fuer medizinische zwecke.
ID24173A (id) 1,2,3,4,5,6 heksahidro-2-6-metano-3-benzazosin-10-ol, proses pembuatan dan penggunannya untuk obat-obatan
DE69728897D1 (de) Saeugetierchemokine
IS4629A (is) Samskeyttar veirukjarnsýrur
EP0622464A3 (de) Verfahren zum Nukleinsäurenachweis.
SK2694U (sk) Aminokyselinové nukleové kyseliny
DE59209120D1 (de) Mittel zur Härtung von hornartigen Körperteilen von Säugetieren
AU8405798A (en) A swine hepatitis e virus and uses thereof
ES2092568T3 (es) Identificacion de nuevos farmacos y reactivos.
FI902814A7 (fi) Proteiineja, rokotteita ja nukleiinihappoja
DK68591A (da) Fremgangsmaade til nukleinsyreamplifikation
GB9413095D0 (en) Novel nucleic acids, methods for their production and uses thereof in assay procedures, in diagnostic tests in the manufacture of therapeutic agents
GB9509804D0 (en) Novel nucleic acids, methods for their production and uses thereof in assay proceedures, in diagnotic tests, in the manufacture of therapeutic agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0778842

Country of ref document: EP